Capital in this category stopped rewarding growth stories around 2023 and has not gone back. Investors now open with profitability questions. A founder who cannot answer them in the first meeting rarely gets a second one. The pitch that worked five years ago describes a market size. The pitch that works now describes a margin.
The reset was severe. Enterprise value to revenue multiples for United States operators have fallen from roughly 6x to around 1x in many cases. The main cannabis exchange-traded fund is down more than 80% from its highs.
Gross Margin, the First Filter
Gross margin is the first number an investor looks at, because it shows the health of the core operation before overhead, taxes and debt service enter the picture. Average gross margins for United States multi-state operators sat in the 43% to 45% range in mid-2024. The companies actually raising money tend to be above 50%.
For a CBD brand specifically, the headline number flatters the business. Supplement and wellness products commonly carry 65% to 80% gross margins, which sounds decisive until acquisition spending and compliance costs come out of it. Investors know this, so they move quickly past the gross line to contribution margin after marketing.
Anyone raising in this category should arrive with both numbers calculated and the bridge between them written down.
Banking Continuity in Diligence
Investors ask about banking early, because companies that cannot reliably take money are not companies. A diligence list names the acquiring relationship, the current rate, the reserve terms, and the contingency if the account closes, and founders who can name their payment processor for CBD sales alongside a second boarded backup are answering a question most of their competitors cannot.
Concentration in a single acquirer is treated the same way as concentration in a single supplier. Both are single points of failure with a revenue number attached.
EBITDA and the 280E Distortion
EBITDA remains the primary valuation metric across the sector, largely because Section 280E of the tax code distorts net income so badly that the bottom line stops carrying information. Plant-touching operators cannot deduct ordinary business expenses, so a profitable company can report a loss while paying tax on gross profit.
Hemp-derived CBD sellers usually fall outside 280E, which is a genuine advantage worth stating explicitly in a data room. Investors accustomed to reading cannabis financials will assume the distortion is present unless the memorandum says otherwise, and correcting that assumption late costs a valuation turn.
Presenting the numbers cleanly means reconciling gross profit to operating profit for every period shown, using the same definitions throughout, with any adjustment labeled where it occurs. Inconsistent definitions across periods read as carelessness at best, and no investor stops at the charitable reading.
The Data Room Standard
Diligence in 2026 is institutional. A slide deck with pro formas no longer counts as preparation. The package investors expect is an organized data room that survives professional scrutiny.
Reconciled financial statements come first, with clean books rather than an accountant’s reconstruction assembled the week before. Documented internal controls come next, including compliance sign-offs and inventory sign-offs that someone actually performed. The balance sheet gets read alongside cash flow, since revenue diversification and liquidity now matter more than topline growth.
Everything a regulator could request should already be filed there. Licenses, certificates of analysis by lot, supplier agreements, the advertising substantiation file, and the merchant application package all belong in the room before anyone asks.
Two things separate a prepared room from an assembled one. The first is versioning, since a folder holding three undated spreadsheets with similar names invites the question of which one is true. The second is an index written by someone at the company rather than exported by software, because the ordering of the material tells an investor how the business understands itself.
Regulatory Exposure After November 2026
The hemp definition narrows on November 12, 2026. Every catalog in the category has to be mapped against it. Anything above a 0.4 mg per-container ceiling for combined THC and comparable cannabinoids drops out of the hemp definition entirely and is reclassified as a controlled substance.
Investors will ask what share of trailing revenue those products represent. Founders who have run that calculation are describing a manageable transition. Those who have not are asking someone else to price an unknown, and unknowns get priced conservatively.
The December 2025 executive order directing expedited rescheduling cuts the other way and belongs in the same memorandum. Rescheduling cannabis would also loosen the constraints on research funding, which over the following years changes the evidence base that every claim in this category depends on. Investors weighing a ten-year horizon care about that more than founders expect.
Valuation in a Reset Market
The United States legal cannabis market reached an estimated $44 billion in 2025 and is projected near $47 billion in 2026, so the growth story is intact while the multiples are not. That gap is the whole negotiation.
Venture capital funds need a small number of large outcomes to return a fund, which shapes what they can accept. In a sector where exits have thinned and public comparables have collapsed, the fund’s own return requirement argues for a lower entry price, and founder conviction does not move it.
Private buyers and strategic acquirers behave differently. Founders raising in this market should know which type of capital they are actually talking to before the first meeting.
Late-Stage Deal Breakers
Deals in this category die late, and usually for the same handful of reasons. Undisclosed regulatory correspondence is the most common. An FDA warning letter or a state enforcement action surfacing in week six of diligence looks like concealment even when the founder simply forgot.
Unmapped affiliate and influencer liabilities come next, followed by a merchant account that turns out to be sitting on a 30-day termination notice nobody mentioned.
Inventory is the quiet one. Stock valued at cost in the accounts but sitting past its stability date is a write-down waiting to be found. Diligence teams check expiry dating against the balance sheet as a matter of routine. Brands that have already taken the write-down look disciplined. Brands that have not look optimistic, and optimism is expensive at this stage.
Founders spend their preparation time learning how to pitch to a VC and almost none of it preparing for week six. The first meeting is a filter. The diligence period is where the price gets set. Every item a founder has to explain under pressure moves that price down. A company that discloses its four worst facts in the first week keeps control of what they mean. One that lets an investor find them keeps nothing.
